Labcorp launches Labcorp OnDemand digital health platform

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 4, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of Labcorp OnDemand, an easy experience where individuals can purchase Labcorp OnDemand tests online, collect samples in the convenience of their home, or schedule test appointments at one of Labcorp’s 2,000 patient service centers (PSCs), including Labcorp at Walgreens locations. The OnDemand platform includes a suite of the company’s most popular tests, including its wellness, allergy, COVID-19, women’s health and fertility tests, to help individuals manage their health and make more informed decisions. A full list of tests available can be found by visiting www.OnDemand.Labcorp.com.

Labcorp named to Fortune® Magazine’s 2022 ‘World’s Most Admired Companies’ list for the fourth time

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 2, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, has been named to FORTUNE® magazine's 2022 list of the World’s Most Admired Companies, marking its fourth appearance on the list. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, asks top executives, directors and financial analysts to identify the companies with the strongest reputations across various industries.

Labcorp earns 100% on Human Rights Campaign Foundation’s annual scorecard on LGBTQ+ Workplace Equality

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 27, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received a perfect score of 100% on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.

Siemens Healthineers launches Enhanced Liver Fibrosis (ELF) test in the U.S.

TARRYTOWN, N.Y., Jan. 26, 2022 —The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF Test is exclusively available through collaborations with Labcorp (NYSE: LH) and Quest Diagnostics (NYSE: DGX), providing access (with a physician’s order) across the country. This is the first time the test is commercially available in the U.S., following De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in August 2021.